Molecular Partners (MOLN) News
NASDAQ: MOLNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MOLN news summary
We found 5 recent headlines mentioning Molecular Partners (MOLN): 0 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. MOLN is making an outsized move today, down 5.25% at $2.53, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Molecular Partners to Present at Inaugural UBS Global Biopharma Conference", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Molecular Partners headlines
- Molecular Partners to Present at Inaugural UBS Global Biopharma ConferenceZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines…GlobeNewswire
- Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines…GlobeNewswire
- Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines…GlobeNewswire
- Molecular Partners AG Announces Strategic Shift to Radiopharmaceuticals and Intends to Reduce Workforce by No More Than 55 PositionsMolecular Partners AG announced a strategic shift to deepen its focus on radiopharmaceuticals and streamline its capabilities and resources, resulting in a pipeline prioritization and operating cost…NasdaqMOLN, SUN
- Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted RadiotherapyZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech…GlobeNewswire